發(fā)布時(shí)間：2018-01-16 15:31

  本文關(guān)鍵詞：雙緩釋藥物支架的制備及其生物學(xué)評(píng)價(jià)　出處：《西南交通大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 陶瓷 多孔材料 殼聚糖微球 聚(乳酸 羥基乙酸)微球 雙緩釋藥物支架

【摘要】：在骨組織工程中,支架材料扮演著重要的角色,它不僅為細(xì)胞的增殖、黏附和細(xì)胞外基質(zhì)的沉積提供生長(zhǎng)模板,還可以引導(dǎo)組織的再生和血管化。但是單純利用生物材料自身組分來(lái)調(diào)控細(xì)胞的行為和促進(jìn)組織再生,其效果是有限的。目前,將促進(jìn)骨生長(zhǎng)的藥物與多孔支架結(jié)合是加速骨組織生長(zhǎng)的理想方法。但是簡(jiǎn)單地將支架浸泡在藥物中,會(huì)導(dǎo)致藥物釋放過(guò)快、釋放時(shí)間短、局部藥物濃度過(guò)高等后果,不能有效地加速骨愈合。研究表明將藥物緩釋體系和支架結(jié)合構(gòu)建藥物緩釋支架能在局部保持長(zhǎng)效而穩(wěn)定的藥物釋放,促進(jìn)成骨細(xì)胞的生長(zhǎng),加速骨修復(fù)。然而目前的研究主要集中在多孔支架與單一藥物緩釋體系的結(jié)合,在骨修復(fù)過(guò)程只能提供一種藥效,不能滿足臨床上復(fù)雜的要求。因此,多孔支架與多級(jí)藥物緩釋體系提供多種藥效協(xié)同促進(jìn)骨組織生長(zhǎng)被認(rèn)為是一個(gè)新方向。本文采用模板浸出法制備了具有優(yōu)良貫通性的羥基磷灰石(HA)支架;分別采用化學(xué)交聯(lián)法和雙乳液/溶劑揮發(fā)法制備載丹酚酸B(Sal-B)的殼聚糖微球(Sal B-CS微球)和載地塞米松(dex)的聚(乳酸,羥基乙酸)微球(dex-PLGA微球)。通過(guò)靜電相互作用將Sal B-CS和dex-PLGA微球依次固定在預(yù)先涂覆海藻酸鹽的多孔HA支架上,干燥后獲得雙緩釋藥物支架(al-HAs/Sal B-CS/dex-PLGA支架)。本文研究了 al-HAs/SalB-CS/dex-PLGA支架的機(jī)械性能和對(duì)細(xì)胞生長(zhǎng)的影響,主要結(jié)果如下:(1)Sal B-CS和dex-PLGA微球均為球形,且具有光滑的表面。Sal B-CS和dex-PLGA微球的平均粒徑分別為27μm、7μm。(2)Sal B-CS和dex-PLGA微球成功地固定在表面涂覆海藻酸鈉的多孔HA支架上,且載Sal B-CS微球均勻并穩(wěn)定地分布在支架表面,dex-PLGA微球圍繞在Sal B-CS微球周圍。(3)制備長(zhǎng)徑比為3:2的長(zhǎng)支架用于力學(xué)實(shí)驗(yàn),測(cè)定幾組不同支架的抗壓強(qiáng)度和孔隙率結(jié)果發(fā)現(xiàn):隨著海藻酸鹽進(jìn)入支架表面微孔,HA支架的抗壓強(qiáng)度從1.06 MPa增強(qiáng)至1.55 MPa。此外,隨著微球與HA支架的結(jié)合,支架的孔隙率降低,但都高于70%,滿足臨床上對(duì)于骨修復(fù)支架的要求。(4)體外動(dòng)力學(xué)實(shí)驗(yàn)結(jié)果表明:與Sal B-CS和dex-PLGA微球相比,al-HAs/SalB-CS/dex-PLGA支架的初期藥物突釋量較低。在30天內(nèi),al-HAs/Sal B-CS/dex-PLGA支架培養(yǎng)液的pH值基本保持7.4不變。(5)用支架浸提液培養(yǎng)成骨細(xì)胞,結(jié)果表明幾組支架均無(wú)細(xì)胞毒性,具有良好的生物相容性。在幾種多孔支架表面培養(yǎng)成骨細(xì)胞發(fā)現(xiàn)大量成骨細(xì)胞粘附在支架表面。成骨細(xì)胞增殖實(shí)驗(yàn)顯示:al-HAs/Sal B-CS/dex-PLGA支架比HA裸支架更利于成骨細(xì)胞的生長(zhǎng)。炎性因子表達(dá)實(shí)驗(yàn)表明,雙緩釋藥物支架下調(diào)IL-6的表達(dá)量;ALP表達(dá)實(shí)驗(yàn)顯示,al-HAs/Sal B-CS/dex-PLGA支架能夠促進(jìn)BMSCs向成骨細(xì)胞分化。
[Abstract]:Scaffolds play an important role in bone tissue engineering. They not only provide growth templates for cell proliferation, adhesion and deposition of extracellular matrix. It can also lead to tissue regeneration and vascularization. However, the effects of regulating cell behavior and promoting tissue regeneration by using biomaterial components alone are limited. The combination of bone growth-promoting drugs with porous scaffolds is an ideal way to accelerate bone tissue growth. But simply immersing the scaffolds in drugs can lead to drug release too fast and the release time is short. Local drug concentration too high can not effectively accelerate bone healing. Studies have shown that the combination of drug delivery system and stent can maintain long-term and stable drug release. Promote the growth of osteoblasts, accelerate bone repair. However, the current research focuses on the combination of porous scaffolds with a single drug delivery system, which can only provide one drug effect in the bone repair process. Can't meet complex clinical requirements. It is considered a new direction that porous scaffolds and multistage drug delivery systems provide synergistic effects to promote bone tissue growth. In this paper, hydroxyapatite (HA) scaffolds with excellent transfixibility were prepared by template leaching. Poly (lactic acid) was prepared by chemical crosslinking method and double emulsion / solvent volatilization method for preparation of chitosan microspheres carrying Salvianolic acid (Bal Sal-B) and dexamethasone (dexamethasone). Sal B-CS and dex-PLGA microspheres were sequentially immobilized on porous HA scaffolds coated with alginate by electrostatic interaction. Double sustained-release drug stents were obtained after drying. (alHAs-Sal B-CS-dex-PLGA stents). The mechanical properties of al-HAs/SalB-CS/dex-PLGA scaffold and its effect on cell growth were studied. The main results are as follows: Sal B-CS and dex-PLGA microspheres are spherical. The average particle size of Sal B-CS and dex-PLGA microspheres with smooth surface is 27 渭 m, respectively. Sal B-CS and dex-PLGA microspheres were successfully immobilized on porous HA scaffolds coated with sodium alginate. The Sal B-CS microspheres are uniformly and stably distributed on the surface of the scaffold. Dex-PLGA microspheres were surrounded by Sal B-CS microspheres. (3: 2) long scaffolds with aspect ratio of 3: 2 were prepared for mechanical experiments. The results showed that the compressive strength of HA scaffold increased from 1.06 MPa to 1.55 MPA with alginate entering the surface of the scaffold. With the combination of microspheres and HA scaffolds, the porosity of the scaffolds decreased, but were higher than 70%. To meet the clinical requirements for bone repair scaffolds. 4) the results of in vitro kinetic experiments showed that: compared with Sal B-CS and dex-PLGA microspheres. The initial drug release of al-HAs/SalB-CS/dex-PLGA stent was relatively low and within 30 days. The pH value of al-HAs/Sal B-CSR / dex-PLGA scaffold culture medium remained basically unchanged at 7.4.) Osteoblasts were cultured with scaffold extract. The results showed that the scaffolds had no cytotoxicity. Osteoblasts cultured on several porous scaffolds were found to adhere to the scaffold surface. B-CSR dex-PLGA scaffolds were more conducive to osteoblast growth than HA bare scaffolds. The expression of IL-6 was down-regulated by double sustained-release drug stents. ALP expression assay showed that Sal B-CSP-PLGA scaffold could promote the differentiation of BMSCs into osteoblasts.
【學(xué)位授予單位】：西南交通大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R318.08

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 戶小偉;李巍;韋達(dá)隆;勞山;;堿性成纖維細(xì)胞生長(zhǎng)因子對(duì)兔骨髓間充質(zhì)干細(xì)胞向成骨細(xì)胞分化的影響[J];山東醫(yī)藥;2016年48期

2 高春梅;柳明珠;呂少瑜;陳晨;黃銀娟;陳遠(yuǎn)謀;;海藻酸鈉水凝膠的制備及其在藥物釋放中的應(yīng)用[J];化學(xué)進(jìn)展;2013年06期

3 高楓;孫桂波;任小宇;聶媛媛;孫靜;秦蒙;孫曉波;;丹酚酸B對(duì)大鼠離體心臟缺血再灌注損傷的保護(hù)作用[J];中國(guó)中藥雜志;2012年03期

4 金麗霞;;藥物緩釋載體材料在醫(yī)藥領(lǐng)域中的研究及應(yīng)用[J];中國(guó)組織工程研究與臨床康復(fù);2011年25期

5 林峰;石杰;;丹參活性成分的藥效藥理作用[J];醫(yī)學(xué)信息(上旬刊);2011年06期

6 許振;許海燕;;基于組織工程應(yīng)用的生長(zhǎng)因子/高分子納米粒子傳遞系統(tǒng)的研究進(jìn)展[J];國(guó)際生物醫(yī)學(xué)工程雜志;2011年01期

7 姬振行;安靜;王德松;羅青枝;;殼聚糖微球的制備與應(yīng)用[J];材料導(dǎo)報(bào);2010年13期

8 高楓;孫桂波;馬博;聶媛媛;孫曉波;;丹參活性成分作用機(jī)制研究的新進(jìn)展[J];中藥藥理與臨床;2009年04期

9 范煥瓊;崔燎;;丹酚酸B對(duì)體外培養(yǎng)新生大鼠顱骨成骨細(xì)胞的影響[J];中國(guó)藥理學(xué)通報(bào);2008年07期

10 王鳳美,陳軍輝,李磊,王小如,黎先春;高純度丹酚酸B的制備工藝研究[J];時(shí)珍國(guó)醫(yī)國(guó)藥;2005年06期

，

本文編號(hào)：1433723